Showing 4141-4150 of 5771 results for "".
- Alimera Sciences Appoints David Dyer, MD, as Chief Retina Specialisthttps://modernod.com/news/alimera-sciences-appoints-david-dyer-md-as-chief-retina-specialist/2479222/Alimera Sciences has announced the expansion of its leadership team with the appointment of David Dyer, MD, as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business exp
- Essilor Receives FDA Breakthrough Device Designation for Essilor Stellest Spectacle Lenshttps://modernod.com/news/essilor-receives-fda-breakthrough-device-designation-for-essilor-stellest-specticle-lens/2479220/Essilor announced that the FDA has granted Breakthrough Device designation to its Essilor Stellest spectacle lens, the company’s new generation lens developed to correct myopia and slow down the progression of myopia in children. The designation of the Essilor’s Stellest spectacle lens as
- Study Examines ImprimisRx’s Proprietary Klarity-C for Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/multicenter-retrospective-study-examines-imprimisrxs-proprietary-klarity-c-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2479218/ImprimisRx, a wholly owned subsidiary of Harrow Health, announced that a study of its Klarity-C Drops (cyclosporine 0.1% ophthalmic emulsion PF) has been published in the peer-reviewed journal, Clinical Ophthalmology.1 Klarity-C is a compounded preservative-free cyclosporine e
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st
- EyeTech Digital Systems Releases the EyeOn Open Eye-Tracking Platformhttps://modernod.com/news/eyetech-digital-systems-releases-the-eyeon-open-eye-tracking-platform/2479214/EyeTech Digital Systems announced the release of its software ecosystem for the EyeOn family of eye-tracking tablets. Software-agnostic EyeOn devices support EyeTech’s applications as well as third-party applications, arming engineers and end users with the highest reliability and lowest in
- Oxurion Appoints Tom Graney, CFA, as Chief Executive Officerhttps://modernod.com/news/oxurion-appoints-tom-graney-cfa-as-chief-executive-officer/2479215/Oxurion NV announced in a planned succession, the promotion of Tom Graney, CFA, from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Patrik De Haes, MD, who after 14 years as CEO has decided to move away from day-to-day management
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi
- First Pediatric Patient with Rare Genetic Eye Disease Dosed in Clinical Trialhttps://modernod.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/ProQR Therapeutics has announced the first pediatric clinical trial participant has been treated in its new clinical trial named Brighten of the experimental RNA therapy sepofarsen. Brighten is a clinical study for children under 8 years old with Leber congenital amaurosis (LCA) d
- Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMDhttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-study-of-gem103-as-an-add-on-to-anti-vegf-therapy-for-the-treatment-of-wet-amd/2479205/Gemini Therapeutics announced the completion of enrollment in its phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular endothelial growth factor (anti-VEGF) treatment who have, or may be at risk for, macular atroph
- Tilak Healthcare Launches US Pilot for OdySight Medical Vision Monitoring Apphttps://modernod.com/news/tilak-healthcare-launches-us-pilot-for-odysight-medical-vision-monitoring-app/2479202/Tilak Healthcare is launching a pilot program in the US with Novartis for OdySight, Tilak’s first clinically tested mobile app for patient remote vision monitoring. The program is the first to launch under an international collaboration announced in 2020 between Tilak Healthcare and